Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
НПВП и гепатотоксичность. Доказана ли безопасность?
НПВП и гепатотоксичность. Доказана ли безопасность?
НПВП и гепатотоксичность. Доказана ли безопасность? Участковый терапевт. 2017; 5: 19.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Врачи всех специальностей, сталкивающиеся с проблемой острой или хронической боли, нуждаются в удобных и надежных инструментах ее контроля. Таким инструментом являются нестероидные противовоспалительные препараты (НПВП).
Полный текст
Список литературы
1. Каратеев А.Е., Насонова В.А. НПВП-ассоциированная гепатопатия: проблема нимесулида. Научно-практическая ревматология. 2003; 4: 87–91.
2. Alegria P, Lebrei L, Chagas C. Celecoxib-induced cholestatic hepatotoxicy in a patient with cirrosis. Ann Inter Med 2002; 137: 75.
3. Boelsterli U. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf 2002; 25: 633–648.
4. Bolder U et al. Sulindac is excreated into bile a canalicular bale salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology 1999; 117: 962–71.
5. Silverstein F, Faich G, Goldstein J et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247–55.
6. Banks A et al. Diclofenak-associated hepatotoxicity: analysis of 180 cases report to the Food and Drug Administration as adverse reactions. Hepatology 1995; 22: 820–70.
7. Grieco A, Miele L, Giorgi A et al. Acute cholestatic hepatitis associated with celecoxib. Ann Pharmacother 2002; 36:1887–9.
8. Mohammed F, Smith AD. Cholestatic hepatitis in association with celecoxib. Classification of drug associated liver dysfunction is questionable. BMJ 2002; 325: 220.
9. Maddrey W, Maurath C, Verburg K, Geis G. The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther 2000; 7: 153–8.
10. Huster D, Schubert C, Berr F et al. Rofecoxib-induced cholestatic hepatitis: treatment with molecular absorbent recycling system (MARS). J Hepatol 2002; 37: 413–4.
11. Carniato A, Vaglia A. Hepatitis-like syndrome induced by nimesulide (case report). Infezioni Med 1997; 4: 256.
12. Sbeit W, Krivoy N, Shiller M et al. Nimesulide-induced acute hepatitis. Ann Pharmacother 2001; 35: 1049–52.
13. McCormick P, Kennedy F, Curry M et al. COX 2 inhibitor and fulminant hepatic failure. Lancet 1999; 353: 40–1.
14. Weiss P, Mouallem M, Bruck R et al. Nimesulide-induced hepatitis and acute liver failure. Isr Med Ass J 1999; 1: 89–91.
15. Rodrigo L et al. Nimesulide-induced severe hemolytic anemia and acute liver failure leading to liver transplantation. Scand J Gastroenterol 2002; 37: 1341–3.
16. Жолобова Е.С., Конопелько О.Ю., Гешева З.В. Гепатотоксичность нестероидных противовоспалительных препаратов, применяемых в детской ревматологии. Педиатрия. 2009; 88 (5): 154–60.
17. Traversa G et al. Cohort study of hepatotoxicity associated with nimesulide and other nonsteroidal anti-inflammatory drugs. BMJ 2003; 327: 18–22.
18. Merlani G., Fox M, Oehen H et al. Fatal hepatotoxicity secondary to nimesulide. Eur J Clin Pharmacol 2001; 57: 321–6 (abstract).
19. Sanchez-Matienzo D. et al. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther 2006; 28 (8): 1123–32.
20. Donati M et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case–control study in Italy. Br J Clin Pharmacol 2016; 82: 238–48.
21. Lapeyne-Mestne M. et al. Fundam Clin Pharmacol 2013; 27 (2): 223–30.
2. Alegria P, Lebrei L, Chagas C. Celecoxib-induced cholestatic hepatotoxicy in a patient with cirrosis. Ann Inter Med 2002; 137: 75.
3. Boelsterli U. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf 2002; 25: 633–648.
4. Bolder U et al. Sulindac is excreated into bile a canalicular bale salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology 1999; 117: 962–71.
5. Silverstein F, Faich G, Goldstein J et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247–55.
6. Banks A et al. Diclofenak-associated hepatotoxicity: analysis of 180 cases report to the Food and Drug Administration as adverse reactions. Hepatology 1995; 22: 820–70.
7. Grieco A, Miele L, Giorgi A et al. Acute cholestatic hepatitis associated with celecoxib. Ann Pharmacother 2002; 36:1887–9.
8. Mohammed F, Smith AD. Cholestatic hepatitis in association with celecoxib. Classification of drug associated liver dysfunction is questionable. BMJ 2002; 325: 220.
9. Maddrey W, Maurath C, Verburg K, Geis G. The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther 2000; 7: 153–8.
10. Huster D, Schubert C, Berr F et al. Rofecoxib-induced cholestatic hepatitis: treatment with molecular absorbent recycling system (MARS). J Hepatol 2002; 37: 413–4.
11. Carniato A, Vaglia A. Hepatitis-like syndrome induced by nimesulide (case report). Infezioni Med 1997; 4: 256.
12. Sbeit W, Krivoy N, Shiller M et al. Nimesulide-induced acute hepatitis. Ann Pharmacother 2001; 35: 1049–52.
13. McCormick P, Kennedy F, Curry M et al. COX 2 inhibitor and fulminant hepatic failure. Lancet 1999; 353: 40–1.
14. Weiss P, Mouallem M, Bruck R et al. Nimesulide-induced hepatitis and acute liver failure. Isr Med Ass J 1999; 1: 89–91.
15. Rodrigo L et al. Nimesulide-induced severe hemolytic anemia and acute liver failure leading to liver transplantation. Scand J Gastroenterol 2002; 37: 1341–3.
16. Жолобова Е.С., Конопелько О.Ю., Гешева З.В. Гепатотоксичность нестероидных противовоспалительных препаратов, применяемых в детской ревматологии. Педиатрия. 2009; 88 (5): 154–60.
17. Traversa G et al. Cohort study of hepatotoxicity associated with nimesulide and other nonsteroidal anti-inflammatory drugs. BMJ 2003; 327: 18–22.
18. Merlani G., Fox M, Oehen H et al. Fatal hepatotoxicity secondary to nimesulide. Eur J Clin Pharmacol 2001; 57: 321–6 (abstract).
19. Sanchez-Matienzo D. et al. Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther 2006; 28 (8): 1123–32.
20. Donati M et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case–control study in Italy. Br J Clin Pharmacol 2016; 82: 238–48.
21. Lapeyne-Mestne M. et al. Fundam Clin Pharmacol 2013; 27 (2): 223–30.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.